

Rowan University

Rowan Digital Works

Stratford Campus Research Day

27th Annual Research Day

May 4th, 12:00 AM

Whole Body Cryotherapy as a Novel Treatment for Long COVID Syndrome Associated Brain Fog

James Mack
Rowan University

Brandon Goodwin
Rowan University

Paras Patel
Rowan University

Kyra Herman
Rowan University

Daniel Casal
Rowan University

Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day

See next page for additional authors



Part of the [Alternative and Complementary Medicine Commons](#), [Health and Medical Administration Commons](#), [Infectious Disease Commons](#), [Investigative Techniques Commons](#), [Pathological Conditions, Signs and Symptoms Commons](#), [Therapeutics Commons](#), and the [Virus Diseases Commons](#)

Let us know how access to this document benefits you - share your thoughts on our [feedback form](#).

Mack, James; Goodwin, Brandon; Patel, Paras; Herman, Kyra; Casal, Daniel; and Levenson, Emily, "Whole Body Cryotherapy as a Novel Treatment for Long COVID Syndrome Associated Brain Fog" (2023). *Stratford Campus Research Day*. 166.

https://rdw.rowan.edu/stratford_research_day/2023/may4/166

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Stratford Campus Research Day by an authorized administrator of Rowan Digital Works.

Author(s)

James Mack, Brandon Goodwin, Paras Patel, Kyra Herman, Daniel Casal, and Emily Levenson

Whole body cryotherapy as a novel treatment for long COVID syndrome associated brain fog

James Mack, OMS-III¹, Brandon Goodwin, OMS-III¹, Paras Patel, OMS-III¹, Kyra Herman, OMS-III¹, Daniel Casal, OMS-II¹, Emily Levenson, OMS-IV²

¹Rowan-Virtua School of Osteopathic Medicine

²A.T. Still University-Kirksville College of Osteopathic Medicine

Background

SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 in Wuhan, China when adults began presenting with severe pneumonia of an unknown cause.¹ SARS-CoV-2 can cause a wide range of clinical manifestations. Individuals can be asymptomatic, but may also experience acute respiratory distress syndrome and multi-organ dysfunction. Common symptoms include fever, cough, sore throat, headache, fatigue, myalgia, and breathlessness.² SARS-CoV-2 can penetrate the olfactory mucosa and may enter the brain through the cribriform plate along the olfactory tract, through vagal or trigeminal pathways, or pass through the blood-brain barrier. Once inside the brain, levels of inflammatory cytokines are increased and can lead to altered learning, memory, neuroplasticity, hallucinations, nightmares, cognitive and attention deficits, new-onset anxiety and depression, and psychosis.³ It has been hypothesized that microglia within the hypothalamus, interacting with mast cells, are responsible for neuroinflammation and proceeding cognitive impairment associated with long-COVID syndrome associated brain fog.⁴ Long-COVID syndrome is characterized by symptoms such as mental fatigue (brain fog), difficulty with multitasking, fatigue, headache, insomnia, irritability, inability to find the right words, memory loss, and weakness.⁴ Brain fog, common in chronic fatigue syndrome, has been described as “slow thinking, difficulty focusing, confusion, lack of concentration, forgetfulness, or haziness in thought processes.”⁵ A theoretical treatment for long COVID syndrome, whole body cryotherapy, involves exposing the entire body, including the head, to ultra-low temperatures for a brief time using an enclosed space referred to as a whole-body cryochamber.⁶ Theories of cryotherapy leading to neuroprotection include decreased neural cell metabolism, which in turn leads to decreased oxygen consumption, glucose consumption, and cerebral blood flow.⁷⁻⁹

Purpose

To evaluate the efficacy of whole body cryotherapy on long COVID syndrome and its current clinical uses.

Methods

A systematic literature review was performed for articles published between 2006-2021 using PubMed and Scopus, with keywords: “coronavirus OR COVID OR COVID-19 OR long COVID” AND “cryotherapy OR cryostimulation OR whole body cryotherapy OR cryochamber OR low temperature” AND “brain fog OR brain OR central nervous system OR CNS” AND “neuroprotection.”

Inclusion Criteria

Types of studies

A variety of different research studies were used while conducting this literature review. Studies used for this literature review included primary research studies, cohort studies, meta-analyses, systematic reviews, randomized controlled trials, longitudinal studies, prospective randomized controlled trials, comparative analyses, and other literature reviews. Journal articles were primarily peer-reviewed.

Types of participants

The focus of this literature review was on adults over 18 who were diagnosed with COVID-19 infection and exhibited symptoms of long COVID syndrome. Journal articles including individuals of both genders, all races, and all ethnicities were evaluated.

Types of interventions

Limits were not placed on the type of intervention type used by these studies in order to obtain as much relevant and useful data in order to evaluate the risks, downstream consequences, and treatment of long COVID syndrome with whole body cryotherapy.

Types of outcome measures

Studies were reviewed with the outcomes of assessing the possible efficacy of whole body cryotherapy on long COVID syndrome. The impact of whole body cryotherapy on long COVID syndrome was evaluated. The efficacy of whole body cryotherapy for other diseases, including Alzheimer’s

Literature Results

Main Findings

Cryotherapy Procedure

- Cryochambers may use an air compressor that separates nitrogen from oxygen, allowing it to sufficiently cool before re-mixing it with the oxygen and ejecting this vapor into the chamber.¹⁰
- The other type of cryochamber technology circulates cold nitrogen throughout the walls of the cryochamber to create a low temperature environment.^{10,11}
- Cryochambers commonly consist of 2 – 3 chambers, the initial chamber(s) at -60 degrees Celsius (or if two initial chambers, at -10 and -60 degrees Celsius respectively) and one main chamber with temperatures ranging from -110 degrees Celsius to -160 degrees Celsius.^{13, 14} Patients will enter the first one (or two) chambers to briefly acclimate (around 30 seconds) and then will proceed to the main chamber where the duration of treatment ranges from 1 to 4 minutes.^{10,11}

Clinical Uses for Cryotherapy

- **Anxiety and depression:** In the literature, WBC at temperatures between -60 degrees Celsius and -110 degrees Celsius has been shown to be a valuable treatment when used in supplement to other mental health interventions such as pharmacotherapy and cognitive behavioral therapy.¹²
- **Fibromyalgia:** Patients with fibromyalgia who received 15 whole body cryotherapy sessions found that those who received whole body cryotherapy, from -60 degrees Celsius to -140 degrees Celsius, had a reduced pain score according to the Visual Analogue Scale.¹³
- **Rheumatoid arthritis:** Studies have shown that morning stiffness and pain intensity via the Visual Analog Scale were decreased in patients with rheumatoid arthritis. Treatment with whole body cryotherapy in patients with rheumatoid arthritis also decreased C-reactive protein and inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha.^{14,15}
- **Multiple sclerosis:** One study found that patients with MS who received WBC between the ranges of -110 degrees Celsius and -160 degrees Celsius saw an improvement in depressive status and functional status¹⁶

Cryotherapy Mechanism of Neuroprotection

- Underlying mechanism currently unknown
- Therapeutic hypothermia has also been shown to decrease lactate production, excitotoxins, and decreased ischemia through the downregulation of CaSR (calcium-sensing receptor) induced GABA release.¹⁷
- Theories of cryotherapy leading to neuroprotection include decreased neural cell metabolism, which in turn leads to decreased oxygen consumption, glucose consumption, and cerebral blood flow.⁷⁻⁹
- Another theory on the neuroprotective mechanisms of therapeutic hypothermia is activation of cold-induced RNA binding protein (CIRBP). CIRBP helps protect against oxidative stress on neural cells and subsequent apoptosis.¹⁸
- cryotherapy can assist in maintaining the integrity of the blood brain barrier through the reduction of matrix metalloproteinases.¹⁸

Cryotherapy Usage in long COVID syndrome

- Currently, the pathogenesis of brain fog associated with COVID is not well understood, but it is hypothesized that neuroinflammation plays a key role.¹⁹
- Patients with severe COVID symptoms have been shown to have decreased cerebral blood flow and increased inflammatory cytokines which have been linked to hypoxic injury to the brain.²⁰
- Malondialdehyde, an antioxidant marker that rises with total antioxidant capacity, has been shown to significantly decrease in patients affected by COVID-19.²¹
- A study involved exposing rats to whole-body cryotherapy and seeing the effects on their antioxidant levels found that malondialdehyde levels were elevated in rats exposed to -60°C temperatures for one minute, however these values were not statistically significant. When the total antioxidant capacity of the rats exposed to cryotherapy was compared with controls, the rats exposed to cryotherapy had a statistically significant increase in total antioxidant levels.²²
- Cryotherapy targeted to the cephalic region could offer a feasible method to relieve some symptoms associated with brain fog associated with long COVID.
- Although the pathophysiology of brain fog associated with COVID-19 has not been fully understood yet, cryotherapy has been shown to modulate many inflammatory processes that coincide with COVID-19.

Efficacy of Cryotherapy

- Several theories have explained the mechanism of whole body cryotherapy as providing neuroprotection against oxidative stress on neuronal cells and decreasing the proinflammatory cytokines.^{1,23}
- A pilot controlled study involving 45 COVID patients with anosmia were assessed using a visual analogue scale (VAS) to evaluate the level of olfactory deficit before, after, and weeks after whole body cryotherapy. The participants in the high dose whole body cryotherapy group reported a higher VAS score after the treatment compared to the low dose whole body cryotherapy group and the control group that received no intervention.²⁴

Future Directions

- Cryotherapy is not currently approved by the Food and Drug Administration.
- The current literature theoretically suggests that whole body cryotherapy may be beneficial as a treatment for long COVID syndrome.
- Further literature review on the neuroprotective mechanisms of whole body cryotherapy will need to be conducted
- Randomized control clinical research trials should be conducted to evaluate the efficacy and possible long-term consequences

Conclusion

Whole body cryotherapy has various medical uses and is used mostly in patients suffering from inflammatory diseases, skin lesions, and neurocognitive diseases. Whole body cryotherapy has been used in post COVID patients with anosmia, which indicates promising future research in patients with COVID induced brain fog patients. Although whole body cryotherapy might be safe and beneficial for patients with COVID induced olfactory dysfunction, further research is needed to confirm the findings of this pilot study and to understand the mechanism of whole body cryotherapy in patients with anosmia.²⁴ Additionally, a limitation to this study is that it heavily relied on self-reported assessments with no blinding procedure.²⁴ Despite the many uses of cryotherapy, more research needs to be conducted to assess the effectiveness of cryotherapy in long COVID syndrome patients and if there are any consequences in doing WBC. The exact mechanism of COVID related brain fog is not well understood, but several theories have explained the possible pathological mechanism behind brain fog such as neural inflammation affecting the level of neurotransmitters in the body. These circulating neurotransmitters such as serotonin, may explain some of the associated symptoms of brain fog. Understanding the underlying mechanism of COVID related brain fog may give better insight on how to treat the condition. Furthermore, the research may help find ways to prevent the complication of brain fog from arising. Further research will need to be done in order to fully assess the efficacy and safety of whole body cryotherapy for long COVID syndrome.

References

1. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). *Indian J Pediatr.* 2020;87(4):281-286. doi:10.1007/s12098-020-03263-6.
2. Alimohamadi Y, Sepandi M, Taghdir M, Hosainiudari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. *J Prev Med Hyg.* 2020;61(3):E304-E312. Published 2020 Oct 6.
3. Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. *JAMA Psychiatry.* 2021;78(6):682-683. doi:10.1001/jamapsychiatry.2021.0500.
4. Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. *BioFactors.* 2021;47(2):232-241. doi:10.1002/biot.11726.
5. Ocan AJ. Caught in the thickness of brain fog: exploring the cognitive symptoms of Chronic Fatigue Syndrome. *Front Physiol.* 2013;4:63. Published 2013 Apr 5. doi:10.3389/fphys.2013.00063.
6. Bouzigon R, Grappe F, Ravier G, Dugue B. Whole- and partial-body cryostimulation/cryotherapy: Current technologies and practical applications. *Journal of Thermal Biology.* 2016;10/01/2016:61-67-81.
7. Kurisu K, Kim JY, You J, Yenari MA. Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease. *Curr Med Chem.* 2019;26(29):5430-5455. doi:10.2174/092986732666190506124836
8. Kurisu K, Yenari MA. Therapeutic hypothermia for ischemic stroke: pathophysiology and future promise. *Neuropharmacology.* 2018;134(Pt B):302-309. doi:10.1016/j.neuropharm.2017.08.025
9. Wu L, Wu D, Yang T, et al. Hypothermic neuroprotection against acute ischemic stroke: The 2019 update. *J Cereb Blood Flow Metab.* 2020;40(3):461-481. doi:10.1177/0271678X19894869
10. Bouzigon R, Grappe F, Ravier G, Dugue B. Whole- and partial-body cryostimulation/cryotherapy: Current technologies and practical applications. *Journal of Thermal Biology.* 2016/10/01/2016:61-67-81. doi:https://doi.org/10.1016/j.jtherbio.2016.08.009
11. Lubkowska A. Cryotherapy: Physiological Considerations and Applications to Physical Therapy. In: Bettany-Saltikov J, Paz-Lourido B, eds. *Physical Therapy Perspectives in the 21st Century: Challenges and Possibilities.* InTech; 2012:155 – 176:chap 7.
12. Doets JRK, Topper M, Nugter AM. A systematic review and meta-analysis of the effect of whole body cryotherapy on mental health problems. *Complementary Therapies in Medicine.* 2021;12/01/2021:63:102783. doi:https://doi.org/10.1016/j.ctim.2021.102783
13. Bettoni L, Bonomi FG, Zani V, et al. Effects of 15 consecutive cryotherapy sessions on the clinical output of fibromyalgic patients. *Clinical Rheumatology.* 2013;09/01 2013;32(9):1337-1345. doi:10.1007/s10067-013-2280-9
14. Sadura-Sieklicka T, Solysiuik B, Karlicka A, Sokolowska B, Kontny E, Księżopolska-Orłowska K. Effects of whole body cryotherapy in patients with rheumatoid arthritis considering immune parameters. *Reumatologia.* 2019;57(6):320-325. doi:10.5114/reen.2019.90825
15. Gizińska M, Rutkowski R, Romanowski W, Lewandowski J, Straburzyńska-Lupa A. Effects of Whole-Body Cryotherapy in Comparison with Other Physical Modalities Used with Kinesitherapy in Rheumatoid Arthritis. *Biomed Res Int.* 2015;2015:409174. doi:10.1155/2015/409174
16. Pawik M, Kowalska J, Rymaszewska J. The effectiveness of whole-body cryotherapy and physical exercises on the psychological well-being of patients with multiple sclerosis: A comparative analysis. *Adv Clin Exp Med.* 2019;11-29:2019:28(11):1477-1483. doi:10.17219/acem/104529
17. Kurisu K, Kim JY, You J, Yenari MA. Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease. *Curr Med Chem.* 2019;26(29):5430-5455. doi:10.2174/092986732666190506124836
18. Wu L, Wu D, Yang T, et al. Hypothermic neuroprotection against acute ischemic stroke: The 2019 update. *J Cereb Blood Flow Metab.* 2020;40(3):461-481. doi:10.1177/0271678X19894869
19. Qin Y, Wu J, Chen T, Li J, Zhang G, Wu D, Zhou Y, Zheng N, Cai A, Ning Q, Manyande A, Xu F, Wang J, Zhu W. Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. *J Clin Invest.* 2021 Apr 15;131(8):e147329. doi:10.1172/JCI147329.
20. Kang J-il, Jeong D-K, Choi H. Effects of microcurrent and cryotherapy on C-reactive protein levels and muscle tone of patients with rotator cuff reconstruction. *Journal of Physical Therapy Science.* 2018;30(1):37-41. doi:10.1589/jpts.30.37
21. Muhanmad Y, Kani YA, Hija S, et al. Deficiency of antioxidants and increased oxidative stress in COVID-19 patients: A cross-sectional comparative study in Jigawa, Northwestern Nigeria. *SAGE Open Medicine.* 2021;9:205031212199124. doi:10.1177/2050312121991246
22. Skrzep-Polozek B, Ronuk E, Wiśniewska B, Owczarek AJ, Chorze P, Sieroń A, Birkoer E, Stygar D. Effect of Whole-Body Cryotherapy on Antioxidant Systems in Experimental Rat Model. *Oxid Med Cell Longev.* 2017;2017:8158702. doi:10.1155/2017/8158702.